Johnson & Johnson at JPMorgan Healthcare Conference Transcript
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So Joaquin, Happy New Year. Great speaking with you today.
Questions & Answers
I thought it might be a good way to start the conversation just with some of your reflections on 2023. It was obviously a very busy, very productive year for the company. So why don't we kick off there, and we can jump on some topics from there?
Thank you, Chris, and good morning, everybody. Yes, 2023 was a very productive year for Johnson & Johnson. We had our Enterprise Business Review Day back in December. And it was a very symbolic moment for us because for the first time, we presented what is the new Johnson & Johnson,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |